Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer with more than 14,000 deaths/year in western countries.¹ The high mortality is mostly due to the frequent presentation at advanced stage, and to primary or acquired resistance to platinum-based therapy. Different studies based on whole-genome, proteomic or transcriptomic profiling studies have defined some of the mechanisms involved in the development of platinum resistance in ovarian cancer.^2–4 However, these results have not yet been translated into effective therapeutic strategies to prevent or overcome platinum resistance.

中文翻译：

---

在卵巢癌患者来源的异种移植物中克服铂获得性耐药

上皮性卵巢癌 (EOC) 是最致命的妇科癌症，在西方国家每年有超过 14,000 人死亡。¹高死亡率主要是由于晚期频繁出现，以及对铂类治疗的原发性或获得性耐药。基于全基因组、蛋白质组学或转录组学分析研究的不同研究已经确定了卵巢癌铂耐药性发展所涉及的一些机制。^2-4然而，这些结果尚未转化为有效的治疗策略来预防或克服铂耐药性。